Gilead Sciences stock falls as investors reassess post-earnings rally

Published on 09/09/2026 at 15:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Gilead Sciences stock is down around 3 percent on September 9, 2026 after a strong post-earnings run, as investors weigh drug-pricing risks against solid HIV-driven growth. The shares had previously benefited from second-quarter revenue gains excluding Veklury.

Photorealistischer Biotech-Campus von Gilead Sciences mit Glaslabor und Wissenschaftlern — Gilead Sciences Forschungscampus mit ISIN US3755581036 modernes Biopharma-Labor Kalifornien Glasfassade Wissenschaftler arbeiten, Illustration mit AI erstellt.

Gilead Sciences, Inc. stock (ISIN US3755581036) is trading lower by about 3.4 percent on September 9, 2026, giving back part of its recent post-earnings gains as investors reassess valuation and ongoing U.S. drug-pricing risks.

Post-earnings pullback after strong Q2 momentum

According to Moomoo on September 9, 2026, Gilead Sciences shares are down 3.4 percent as the market digests a strong rally following the company’s second-quarter 2026 earnings update.

In that second-quarter 2026 update, Gilead reported that product sales excluding its COVID-19 antiviral Veklury increased 10 percent year over year, while sales of its flagship HIV regimen Biktarvy grew 7 percent over the same period, underscoring robust demand in its core virology franchise as detailed by Moomoo.

Profit volatility and policy risk temper sentiment

The same second-quarter 2026 earnings release included a large GAAP net loss driven by acquired in-process research and development charges and tax expenses, which creates more volatile bottom-line results even as underlying product revenue trends remain positive, according to Moomoo.

In its latest quarterly filing discussed by Moomoo, Gilead highlighted that the long-term impact of U.S. most-favored-nation pricing arrangements, Medicaid payment model changes, tariffs and broader trade actions on its business remains uncertain, reinforcing policy risk as a key factor for investors to monitor.

Collaboration activity adds to long-term growth story

Beyond quarterly figures, Gilead continues to expand its pipeline through external collaborations. As Moomoo/Globe Newswire reported on September 8, 2026, Assembly Biosciences has exercised its option to share 40 percent of development costs and profits in the United States for its herpes simplex virus helicase-primase inhibitor program for recurrent genital herpes under its collaboration agreement with Gilead Sciences, signaling continued investment in future virology assets.

In addition, Gilead marked a strategic milestone in research infrastructure. According to Las Vegas Sun on September 8, 2026, the company opened a 182,000-square-foot Research Center at its Foster City headquarters to expand capabilities in oncology, inflammation and research data science, aimed at advancing the next generation of medicines.

Stock level and investor takeaway

On Nasdaq, Gilead Sciences stock recently traded around a level that is roughly 3.4 percent below its prior close as of September 9, 2026, reflecting a normal pullback after a period of strength and increased sensitivity to U.S. drug-pricing debates. For investors, the combination of double-digit product sales growth excluding Veklury in second-quarter 2026, 7 percent year-over-year Biktarvy sales growth in that same period, and visible collaboration and research investment underlines a solid fundamental backdrop, even as policy risk and earnings volatility can lead to short-term share price fluctuations.